You picked up your first Wegovy® pen. You read the label, you watched the demo video, and now you’re looking at the dose-escalation schedule wondering what the next 4 months actually feel like — beyond the bullet points.
This guide is the simple walkthrough. We will cover the standard escalation schedule for Wegovy®, what changes week to week, how to time meals around the injection, and when to talk to your prescriber about slowing down.
Everything below is drawn from the Wegovy® prescribing information and the published STEP 1 trial of this FDA-approved branded medication. Results and side-effect rates apply only to the FDA-approved branded product studied; they do not apply to compounded preparations.
Key takeaways
The starter dose (0.25 mg) is not therapeutic for weight loss — it is a tolerance-building step.
Most side effects on Wegovy® peak in the first two weeks after each step-up.
The label allows you to slow down or pause a step-up if tolerability is the limiting factor.
Trial results cited here apply only to the FDA-approved branded Wegovy® studied in STEP 1; they do not apply to compounded preparations.
The standard Wegovy® escalation schedule
Per the Wegovy® prescribing information, the label dose-escalation schedule is:
| Weeks | Wegovy® dose | What it is |
|---|---|---|
| 1–4 | 0.25 mg / week | Starter / tolerance-building dose |
| 5–8 | 0.5 mg / week | First therapeutic step |
| 9–12 | 1.0 mg / week | Second therapeutic step |
| 13–16 | 1.7 mg / week | Third therapeutic step |
| 17 onward | 2.4 mg / week | Maintenance (long-term) |
Schedule is from the Wegovy® FDA-approved prescribing information. Results and tolerability data referenced throughout this guide apply only to the FDA-approved branded Wegovy® product studied in STEP 1; they do not apply to compounded preparations.
The 0.25 mg starter dose is not therapeutic for weight loss. Its only job is to let your body acclimate before the first therapeutic step at week 5.
Weeks 1–4: starter dose (0.25 mg)
The first four weeks on Wegovy® are an acclimation period. Most people feel nausea, fullness, and a small reduction in appetite, but actual weight change is minimal at this dose. The point is to give your stomach and gut time to adjust to the slower gastric emptying that GLP-1 medications produce.
What helps in this phase:
- Smaller, more frequent meals. Three large meals tend to feel worse than five small ones.
- Hydration. Aim for steady water intake — dehydration makes nausea worse.
- Avoid the foods that already sit heavy for you (greasy fried food, large servings of red meat). Most people tolerate lean protein, soft vegetables, and clear soups well.
Weeks 5–8: first step up (0.5 mg)
The first step up to 0.5 mg is where most people notice the appetite-suppression effect kick in. Reduced hunger, earlier fullness, and a quieter relationship with food cues are common. Some people also see the first noticeable weight change in this window.
Side effects often resurface for a few days after the dose change as the body recalibrates to the new level. Nausea typically returns mildly and settles within a week or two.
Weeks 9–12 and 13–16: continued escalation
Steps to 1.0 mg and 1.7 mg work the same way. Each step-up is followed by a short period (often 3–7 days) where side effects can spike, then settle. This is the pattern to expect and to plan around.
The label allows you to stay at a dose longer than four weeks if you need more time at that level. There is no medal for getting to maintenance faster — slow escalation is the single biggest factor in staying on the medication.
Week 17 onward: maintenance (2.4 mg)
The maintenance dose is what the STEP 1 trial of Wegovy® evaluated long-term. In that trial of this FDA-approved branded medication, the average weight loss over 68 weeks at the 2.4 mg maintenance dose was 14.9% of body weight.
Some people land at a lower dose (1.7 mg) for maintenance if the side-effect tradeoff at 2.4 mg is not worth it for them. This is a conversation to have with the prescriber.
How to time meals around the injection
There is no required relationship between the Wegovy® injection and meal timing. Most people pick an injection day and time that fits their week and stay consistent. A few practical patterns we hear from people on Wegovy®:
- Sunday evening injection. Peak side effects often fall on Monday and Tuesday — convenient if your work week is desk-based and your weekend is more social.
- Friday morning injection. Side effects peak over the weekend, which some people prefer so it does not affect the work week.
- Wednesday injection. Splits the week so the peak side-effect days never land at the same time as social obligations.
Experiment in the first month. Pick whichever pattern lets you eat and sleep most normally.
When to talk to your prescriber about slowing down
Call your prescriber if:
- Nausea at any dose is severe enough that you cannot keep fluids down.
- Vomiting persists for more than 48 hours.
- You notice severe upper-abdominal pain (a possible sign of pancreatitis — listed in the Wegovy® label warnings).
- You see yellowing of the eyes or skin.
- Constipation does not respond to fiber + fluids over a week.
- You feel persistently weak or dizzy.
Most of the time, the right move is to stay at the current dose for an extra month before stepping up — not to stop the medication. Bring this option up explicitly with your prescriber.
A note on compounded preparations
Some licensed telehealth providers offer compounded preparations instead of the FDA-approved branded Wegovy®. Compounded preparations are made by state-licensed compounding pharmacies. They are not FDA-approved. They have not been evaluated by the FDA for safety, effectiveness, or quality. They are not generic versions of, or equivalent to, the FDA-approved branded Wegovy®. The escalation schedule and trial results discussed in this article apply only to the FDA-approved branded Wegovy® product; they do not apply to compounded preparations.
Frequently asked questions
Can I skip the 0.25 mg starter dose?
The label does not allow skipping the starter dose. Starting at a higher dose dramatically increases the rate of nausea and vomiting in the published trials of the FDA-approved branded Wegovy®. Stick to the schedule.
What if I miss a weekly dose?
If less than 48 hours have passed since the missed dose, take it as soon as you remember. If more than 48 hours have passed, skip the missed dose and take the next dose on the regular day. Do not double up.
Can I move my injection day mid-treatment?
Yes. The Wegovy® label allows the injection day to be changed as long as at least 2 days (48 hours) separate the doses.
How long until I see weight change on Wegovy®?
Most people see meaningful weight change between weeks 8 and 16 (at the 1.0 mg or 1.7 mg dose). Weight change in the first four weeks at 0.25 mg is usually small. The published STEP 1 trial of the FDA-approved branded Wegovy® measured outcomes at 68 weeks; the average weight loss was 14.9%.
Is the maintenance dose 2.4 mg required?
No. Some people land at 1.7 mg for maintenance if that is the best tradeoff between effect and side effects for them. The 2.4 mg maintenance dose is what was studied in the STEP 1 trial of the FDA-approved branded product; results at lower maintenance doses will be lower.
Can I switch from Wegovy® to Zepbound® partway through escalation?
Yes, this is a conversation with your prescriber. Most prescribers will start you at Zepbound®’s 2.5 mg starter dose, not at a comparable mid-escalation dose.
Sources
- U.S. Food and Drug Administration. Wegovy® Prescribing Information. 2024 revision. fda.gov
- Wilding JPH, et al. STEP 1 trial of Wegovy® (semaglutide brand). New England Journal of Medicine. 2021. PubMed 33567185
- Davies MJ, et al. STEP 2 trial of Wegovy® in adults with type 2 diabetes. The Lancet. 2021. PubMed 33667417
Last updated: 2026-06-11 · Editorially reviewed by the Peptides.io team
Important notices & disclaimers
Editorial & medical: This guide is general education, not medical advice. Talk to a licensed clinician before starting, stopping, or changing any medication.
Affiliate disclosure: Peptides.io may earn a commission from links to providers — it never changes what you pay or how we rank them, and never influences our recommendations.
Compounded GLP-1 (FDA): Compounded semaglutide and tirzepatide are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. They are not generic versions of, or equivalent to, branded medications such as Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Clinical-trial results cited here apply only to those branded formulations — not to compounded preparations.
See the top Weight Loss brands, compared
The real providers we've vetted — scored side by side, so you can pick what fits your goal and get started, not just read.
See the picks →
Comments